ArticleTransplantation direct2026
Clinical Utility of Standardized Genetic Testing in Kidney Transplant Candidate Evaluation.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Evaluation Practices in Living Kidney Donor Candidates.Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Genetic testing is increasingly used in the evaluation of kidney transplant (KT) candidates, yet its direct association with transplant-related outcomes remains unclear. This study assessed whether genetic test results are associated with key steps in the KT process. Methods: In this observational cohort study, 270 KT candidates underwent standardized genetic testing between January 2021 and November 2024. The outcomes, including waitlisting and transplantation, were compared between candidates with and without positive results. Primary outcomes assessed clinical utility during transplant evaluation, including diagnostic reclassification of end-stage kidney disease (ESKD), effects on living donor evaluation, and genetic counseling. Secondary outcomes included waitlisting, transplantation, and post-transplant allograft function (estimated glomerular filtration rate). Results: Among 270 KT candidates, indications for testing included family history (45.9%), hypertension-attributed ESKD without biopsy (30%), and ESKD of unknown etiology (24.4%). Positive genetic results were identified in 104 candidates (38.5%), who were younger and more frequently Black. Family history independently predicted a positive result (adjusted odds ratio = 1.91 and 95% confidence interval, 1.13-3.27; Conclusions: Genetic testing demonstrated a high diagnostic rate among KT candidates, particularly in identifying
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.